These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23270475)

  • 21. A case of infliximab-induced psoriasis.
    Richetta A; Mattozzi C; Carlomagno V; Maiani E; Carboni V; Giancristoforo S; D'Epiro S; Bruni F; Calvieri S
    Dermatol Online J; 2008 Nov; 14(11):9. PubMed ID: 19094847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reactivation of dormant cutaneous Leishmania infection in a kidney transplant patient.
    Mirzabeigi M; Farooq U; Baraniak S; Dowdy L; Ciancio G; Vincek V
    J Cutan Pathol; 2006 Oct; 33(10):701-4. PubMed ID: 17026523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB; Bond MI
    Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions.
    Lecluse LL; Piskin G; Mekkes JR; Bos JD; de Rie MA
    Br J Dermatol; 2008 Sep; 159(3):527-36. PubMed ID: 18627374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atypical cutaneous tuberculosis in a patient with rheumatoid arthritis treated with infliximab.
    Asano Y; Kano Y; Shiohara T
    Acta Derm Venereol; 2008; 88(2):183-4. PubMed ID: 18311458
    [No Abstract]   [Full Text] [Related]  

  • 28. [Pulmonary tuberculosis associated to adalimumab: a study of 3 cases].
    Blanco Pérez JJ; Aranda Torres A; Pego Reigosa JM; Núñez Delgado M; Temes Montes E; Guerra Vales JL
    Arch Bronconeumol; 2010 Apr; 46(4):203-5. PubMed ID: 19896259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutaneous leishmaniasis associated with anti-tumour necrosis factor-α drugs: an emerging disease.
    Marcoval J; Penín RM; Sabé N; Valentí-Medina F; Bonfill-Ortí M; Martínez-Molina L
    Clin Exp Dermatol; 2017 Apr; 42(3):331-334. PubMed ID: 28239885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to improve the safety of biologic therapy in Crohn's disease.
    Ferkolj I
    J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cutaneous leishmaniasis with histopathologic pattern of non-necrotizing granulomatous dermatitis in patients treated with adalimumab.
    Romero-Maté A; Martínez-Sánchez D; Tardío JC; Moreno-Torres A; García-Donoso C; Aguado-Lobo M; Espinosa-Lara P; Borbujo J
    Dermatol Online J; 2012 Sep; 18(9):7. PubMed ID: 23031374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteomyelitis occurring during infliximab treatment of severe psoriasis.
    Sri JC; Tsai CL; Deng A; Gaspari AA
    J Drugs Dermatol; 2007 Feb; 6(2):207-10. PubMed ID: 17373180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
    Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
    Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
    Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.
    Kalb RE; Gurske J
    J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactivation of latent granulomatous infections by infliximab.
    Wallis RS; Broder M; Wong J; Lee A; Hoq L
    Clin Infect Dis; 2005 Aug; 41 Suppl 3():S194-8. PubMed ID: 15983899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
    Clementine RR; Lyman J; Zakem J; Mallepalli J; Lindsey S; Quinet R
    J Clin Rheumatol; 2010 Sep; 16(6):274-9. PubMed ID: 20808167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis.
    Dean KE; Hikaka J; Huakau JT; Walmsley RS
    J Gastroenterol Hepatol; 2012 Mar; 27(3):487-92. PubMed ID: 22098019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy.
    Danko JR; Gilliland WR; Miller RS; Decker CF
    Scand J Infect Dis; 2009; 41(4):252-5. PubMed ID: 19266397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An atypical presentation of visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with infliximab.
    Kritikos K; Haritatos E; Tsigkos S; Gounari P; Skrapari I; Gounaris T; Sioula E
    J Clin Rheumatol; 2010 Jan; 16(1):38-9. PubMed ID: 20051756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.